Programmable nucleases allow defined alterations in the genome with ease-of-use, efficiency and specificity. Their availability has led to accurate and widespread genome engineering, with multiple applications in basic research, biotechnology and therapy. With regards to human gene therapy, nuclease-based gene editing has facilitated development of a broad range of therapeutic strategies based on both non-homologous end-joining and homology-dependent repair. This review discusses current progress in nuclease-based therapeutic applications for a subset of inherited monogenic diseases including cystic fibrosis, Duchenne muscular dystrophy, diseases of the bone marrow and haemophilia, and highlights associated challenges and future prospects.
INTRODUCTION
There are five-eight thousand monogenic diseases, defined as inherited conditions arising from mutations on a single gene 1 . These often manifest during childhood and lead to morbidity and sometimes premature death. While each monogenic disease is rare, it has been estimated that together they will affect about 6% of people at some point in their lives 1 . Diagnosis and treatment for these diseases remain largely insufficient and the care is primarily palliative, focusing on disease management without addressing the underlying genetic defects. The realisation of the social and economic importance of rare diseases and the acute need for diagnostics and treatments has led to initiatives like the International Rare Disease Research One major challenge to the development of a therapeutic strategy for CF is the huge diversity of mutation types. ΔF508 (deletion of phenylalanine at codon 508) mutation, with a prevalence of >80% in CF patients, is by far the most common but more than 1,990 CFTR-mutations have been described 9 . They cause premature stop codons, aberrant splicing, incorrect protein folding or trafficking to the cell surface, and dysfunctional CFTRs with limited channel opening capacity 9 . Pharmacological interventions have been targeted to several of these processes, in the form of: (i) read-through therapeutics, which recognise premature stop codons, thereby allowing full-length protein production and a decline in associated nonsense-mediated decay 10 ;
(ii) correctors, which enable slightly misfolded proteins to evade endoplasmic reticulum quality control and insert at the primary epithelia 11 ; and (iii) potentiators, which target gating mutations and increase channel opening 8, 12 . One prominent drug, the potentiator Ivacaftor (Kalydeco), has demonstrated significant improvement of numerous clinical endpoints such as forced expiratory volume (FEV), weight gain, reduction of hospital admissions (related to requirement of IV antibiotic administration) and increase in lung clearance index in diverse patient subsets bearing the G551D-CFTR missense mutation [13] [14] [15] [16] . Ivacaftor also demonstrated clinical benefit in other gating mutation types: G1244E, G1349D, G178R, G551S, G970R, S1251N, S1255P, S549N and S549R, with G970R being one exception 17 . In the case of ΔF508, ivacaftor has been tested in a Phase 3 clinical trial in combination with lumacaftor 18 . The improvements seen in FEV were modest compared to ivacaftor monotherapy in G551D studies 13, 15 . Thus, while drug administration is therapeutic in some gating mutation types, the commonly occurring ΔF508 still requires a more effective treatment. QR-010 is a drug based on modified single stranded RNA and designed to repair ΔF508 mRNA; research in human cell lines 7 and mice appears promising and is currently progressing to a phase 1b clinical trial 19, 20 .
However, this still would not address mutations resulting from aberrant splicing; it is in these instances gene editing could prove most beneficial.
The premise of permanent correction by gene-editing, as opposed to drug and recent non-viral gene therapy treatments (previously reviewed 9, 21 ) which require repeated administration, is promising. Such CFTR correction at the genome level has been trialled across many of the geneediting platforms. ZFNs were first used to achieve HDR-mediated knock-in of a 4.5 kb genomic donor harbouring CFTR exons 10-24. The efficiency in patient-derived epithelial cells was modest, with DNA cleavage as measured by NHEJ estimated at 7.8% and the subsequent HDR occurring at <1%, respectively
22
. The ΔF508 mutation was targeted and functional repair obtained in stem cell organoids, using CRISPR-Cas9-mediated HDR and an exon 11 and puromycin resistance-containing DNA donor. In most instances, this resulted in a heterozygous phenotype or mono-allelic correction. Moreover, the forskolin-induced swelling assay, which demonstrates functional correction of the organoids via fluid secretion into the epithelia, showed more improvement than chemical correctors 23, 24 . Although for stem cell organoids there are colon engraftment data, extension of these studies to lung would be helpful to assess focused upon mutation-specific strategies using pharmacological and gene therapy approaches.
Many of the current approaches, such as exon skipping, aim to restore the reading frame by targeting mRNA, masking splice sites or enhancers of exons that shift the reading frame 34, 35 .
The aim of these strategies is to produce a truncated but viable dystrophin protein, resulting in a clinically milder Becker rather than Duchenne muscular dystrophy phenotype 36 .
Genome editing approaches for DMD include promoting permanent exon removal
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, and HDRmediated cDNA knock-in 38, 39 . Notable demonstrations in primary patient myoblasts have been the permanent excision of exon 51 (which would be applicable to 13% of patients) achieved using ZFNs, leading to restoration of the reading frame in an approach akin to exon skipping 40 , and permanent removal of exons 45-55 by multiplexed Cas9 (Fig. 1b) . The latter is a mutational hotspot which if targeted could be therapeutically applicable for 62% of patients 37 . Both of these approaches result in a truncated but functional dystrophin protein 41 . The mutational hotspot has also been targeted by HDR, with meganuclease-mediated repair of exons 45-52 in immortalised patient cells 38 . The benefit of the HDR-mediated approach is that the subsequent correction would enable the restoration of full-length dystrophin (Fig. 1b) .
DMD has also been restored by genome editing in iPSCs from a patient lacking exon 44 by three different strategies: exon 45 skipping by disruption of its splicing acceptor, Indel-mediated frameshift of exon 45, and exon 44 knock-in, utilising both TALEN and CRISPR-Cas9 showing correction ranging from 2-100%; this type of work could establish the level of dystrophin expression required to provide therapeutic benefit, which is currently predicted to be between 15-20% 43 . Two genotypically distinct rat models have also been produced, one with a C>T nonsense mutation in exon 23 analogous to that of the mdx mouse, and another with a large deletion spanning exons 6-13 44, 45 . Additionally, the use of CRISPR-Cas9 in pigs and nonhuman primates for the generation of DMD phenotypes, demonstrates that such gene-editing can be easily transitioned into larger animals [46] [47] [48] . This ease of generation of new DMD animal models allows for a range of mutation types to be produced, thereby providing a greater diversity of models for translational research. Moreover, larger animal models such as rats, pigs and primates tend to exhibit muscle phenotypes such as fibrosis, which is more representative of the clinical manifestations seen in patients than those in the commonly used mdx mouse 49, 50 .
Thus, such models could serve to enrich our understanding of DMD at large and produce more robust and reliable end-points to determine efficacy of treatments.
DISORDERS OF THE BONE MARROW
Bone marrow diseases comprise a variety of conditions including severe anaemic haemoglobinopathies and over 250 different primary immunodeficiencies (PIDs). Current treatment modalities include transfusion of blood, or blood-derived products such as erythrocytes, immunoglobulins and platelets. However, haematopoietic stem cell (HSC) transplantation remains the only curative therapy to achieve permanent reconstitution. Despite the growing number of donor depositories, a human-leukocyte-antigen matched donor cannot be found for some patients. In these cases gene therapy using gene addition in autologous patient cells may offer a potentially safe and efficacious strategy. Successful and durable reconstitution using retroviral and/or lentiviral vectors has been achieved in patients suffering with various bone marrow disorders, including X-linked severe combined immunodeficiency
, adenosine deaminase (ADA) deficiency [53] [54] [55] [56] [57] , Wiskott-Aldrich syndrome 58, 59 , and β-thalassemia 60,61 .
Haemoglobinopathies: Beta-thalassemia and sickle cell anaemia
Haemoglobinopathies or 'genetic anaemias' result from defects of mature haemoglobin. Both . SCA is one of the most common monogenic diseases with over 250,000 cases every year and is a major cause of morbidity and mortality worldwide 63 .
Although non-targeted gene augmentation for haemoglobinopathies has made considerable progress 60, 61, 64 , the high levels of gene expression required and the potential risk of insertional mutagenesis associated with uncontrolled viral integration remain challenging. Editing the HBB locus using programmable nucleases can instead allow for permanent β-globin correction.
Recently, TALENs were used to achieve ~20% HDR-mediated knock-in of therapeutic β-globin full-length cDNA to the endogenous β-globin locus in K562 erythroleukemia cells 65 . Such a strategy would result in expression of β-globin from the cDNA instead of wild-type genomic sequence and would be therapeutic for both SCA and β-thalassemia. Separately, ZFNs were used to repair the SCA point mutation in CD34+ HSC progenitor cells (HSPCs 
Primary immune deficiencies
Primary immune deficiencies comprise a heterogeneous group of rare diseases in which part of the immune system is missing or functions improperly. On the clinical spectrum, severe Similarly, a rat model of SCID-X1 has been generated using ZFNs 86 
HAEMOPHILIA
Haemophilia is a group of inherited bleeding disorders that affect the blood clotting process. . Building up on this, a separate study demonstrated correction of a ~600 Kb inversion using CRISPR-Cas9 system in iPSCs derived from haemophilia A patients 101 . This was achieved by using Cas9 nucleases with target sites on either side of the inversion. Corrected iPSC colonies were clonally expanded before differentiating into epithelial cells, which produced FVIII protein in vitro. Transplantation of corrected endothelial cells rescued injury mortality in haemophilic mice in a short-term experiment 101 .
Haemophilia gene therapy is a forerunner in the field, with promising clinical development using safer viral vectors. Although the genome editing strategies outlined here are still under development and currently lack safety validation, they can be combined with existing advancements such as AAV-vector mediated delivery to the liver to further clinical application.
Furthermore, manipulation of the albumin locus may allow for this condition to be treated in the absence of nucleases, and the locus could also be used as a 'safe harbour' for expression of other secreted proteins 99 .
CONCLUSION
The past few years have seen notable demonstrations of genome editing being applied across a multitude of diseases. Whilst the application of nucleases holds significant therapeutic promise, optimum progress can only be achieved by examining the advancement of gene editing holistically. A number of ubiquitous challenges need to be considered, mostly relating to efficacy of genome editing at the target sequence, safety concerns related to nucleaseassociated off-target effects and delivery of gene editing tools.
Editing efficiency is dependent upon the DNA repair process being relied upon. In instances where the desired effect can be achieved by NHEJ, the correction will most likely occur at a relatively high frequency as NHEJ is the major repair pathway in mammalian cells, although the usefulness of this approach may be limited by the stochastic nature of the Indels being formed.
As discussed earlier, NHEJ has been used to mediate disruption of coding and regulatory sequences, targeted deletions of exons or large intervening sequences and disruption of splice sites. Methods that can predict and evaluate micro-homology sites can be used to bias the 20 repair towards frameshift mutations in protein coding sequence 102 . This would partially address the potential reduction in efficiency caused by micro-homology-mediated end joining, a secondary end-joining pathway with a bias for in-frame deletions 103 .
Precise HDR-based locus alterations allow targeted insertion or in situ correction of mutated DNA sequence, which are suitable for a large subset of disease-causing mutations. However, they are reliant upon homologous recombination, which is normally limited to S and G2 phases of the cell cycle, requires a DNA template and inherently occurs at lower frequencies. HDR- Specificity of genome editing is one of the major safety concerns for translational research.
Owing to sequence similarities within the genome, endonucleases can cleave and modify offtarget regions that are distinct from the site of interest. Off-target effects can lead to unwanted genetic modifications causing cellular stress, functional impairment or enhancement, and oncogenicity, all of which could have detrimental effects clinically 105 . Considerable work is being undertaken to increase fidelity through better design of nuclease components, which has led to improved variants such as megaTALs 106 , dead Cas9-Fok1 fusion nucleases 107 , Cas9 nickases 108 and Cas9 nucleases with truncated guide RNAs 109 . Furthermore, screens of bacterial strains have led to discovery of several alternative Cas9-nucleases with varying specificities [110] [111] [112] [113] .
More recently, Cpf1, a prominent CRISPR variant that requires a shorter RNA and generates a staggered cut which could improve HDR, has also been described This may undergo one of two major repair pathways known as non-homologous end joining (NHEJ) or homology directed repair (HDR), depending upon cell cycle stage and availability of a DNA donor template. NHEJ is an error prone mechanism, which causes small insertions or deletions (Indels) upon ligating the ends of the DNA break. HDR is a precise mechanism which repairs the break by using a homologous donor template.
(b) Functional gene editing strategies using DNA repair pathways. 1) NHEJ can be used to disrupt genomic sequences as a consequence of Indels. This can cause frameshift mutations leading to an early stop codon (or restoration of the reading frame by splice site disruption). 2) NHEJ can mediate targeted deletions. This requires generation of DSBs on both sides of the target genomic sequence, which then deletes the intervening sequence while NHEJ re-joins the DNA ends. 3) HDR can be used to correct a specific mutation by introducing a nuclease-mediated DSB (in proximity to the target site) in the presence of a homologous donor DNA containing corrective sequence. Upon recombination, the repair template corrects the mutated locus. 4) Likewise, by supplying exogenous DNA on the donor template flanked between regions of homology, HDR can be used to mediate targeted gene insertion or knock-in.
(c) Schematic diagram comparing ex vivo and in vivo approaches. In vivo approaches involve direct transfer (denoted by the syringe) of genome editing reagents such as programmable nucleases and donor templates to the human body. In this instance, two prominent gene transfer agents, viral vectors and
